NV SJR10

Urges Congress to increase federal funding for research into therapeutic applications of psychedelic compounds (psilocybin, psilocin, DMT, ibogaine, mescaline, and MDMA) for treating mental health conditions, substance use disorders, and chronic pain

Calls for rescheduling these compounds from Schedule I to a classification that better reflects their therapeutic value, low abuse potential, and safety under medical supervision, prioritizing those with FDA Breakthrough Therapy designation

Requests establishment of a streamlined research approval process and compassionate medical use pathway under the Right to Try Act for terminal or life-threatening conditions

Seeks federal legal protections against prosecution for individuals and entities complying with state laws on supervised adult use of psychedelic compounds

Cites clinical trial results showing 67% of severe PTSD patients no longer met diagnostic criteria after MDMA-assisted therapy, and veterans experienced 88% reduction in PTSD symptoms with ibogaine treatment